Studying immune cells in people with chronic hepatitis B
Examines blood samples from adults with chronic hepatitis B to find gene changes.
Plain-language title generated from the registry record
Registry title: Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Key facts
- Where
- Limoges and Lyon, FranceSee the 3 sites
Where in France
- Centre d'Investigation CliniqueLimoges, FranceTaking people
- Limoges university hospitalLimoges, FranceTaking people
- Hospice civils de LyonLyon, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Limoges
- Trial code
- NCT06853886
- Record updated
- 20 May 2026
- Original description
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.Read full original descriptionShow less
Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation
Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.
Inclusion: Male or female, age ≥18 years old; HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog; Willing and able to provide written informed consent; Affiliated with a social securityregimen; Healthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:; Male or female, age between 18 and 80 years; Willing and able to provide written informed consent.
Exclusion: Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer); Acute hepatitis in the year preceding recruitment; Other liver diseases : alcohol, obesity (BMI>30), diabetes, metabolic syndrome (dyslipidemia and/or known hypertension) - Underlying immunological or cancerous diseases; Positive HCV, HIV or HDV test in a patient; Positive HBV, HCV, HIV or HDV test in a healthy volunteer; Patient with a disability that prevents him/her from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship; Pregnant or breast-feeding women; Secondary exclusion criteria:; A healthy volunteer whose vaccination status does not match that expected on the basis of serological results; Positive blood pregnancy test on inclusion.